A recent study sheds light on the complex interplay between muscle activity and brain function, suggesting that muscle signals may play a significant role in cognitive health, particularly regarding Alzheimer’s disease.
Muscle: a key player in Alzheimer’s research
Traditionally seen merely as a source of strength, muscle tissue actually functions as a communication organ. When muscles contract, they release myokines -chemical messengers that travel through the bloodstream. This muscular messaging acts like an internal courier service between organs.
Among the various myokines, cathepsin B has garnered particular interest. This protein, associated with physical exertion, is thought to influence neurogenesis, the process by which new neurons are formed. Researchers are keen to study it because the hippocampus, a crucial area for memory, is often compromised early in Alzheimer’s disease.
The study’s approach and its implications
The research team, led by Alejandro Pinto and Henriette van Praag, investigated genetically modified APP/PS1 mice, which develop amyloid plaques and cognitive impairments. They employed a viral vector to elevate cathepsin B levels in skeletal muscle.
This treatment targeted muscle rather than the brain. Over several months, the treated mice performed better on spatial memory and learning tests, resembling the memory profiles of healthy mice, according to findings published in 2025.
The intrigue of cathepsin B despite amyloid plaques
One of the most revealing aspects of the study was the biological decoupling observed. Even as amyloid plaques and inflammation in the brain persisted, cognitive performance improved. This underscores a potential brain resilience rather than a straightforward removal of lesions.
In this context, cathepsin B might serve as a repair aid, promoting proteins that support synaptic plasticity -the ability of neural connections to adapt. Memory also relies heavily on this adaptability of neural circuits.
However, this data does not automatically transform cathepsin B into a treatment. Animal models are useful for testing mechanisms, similar to how blueprints help understand a building. Transitioning to human applications will need further trials addressing safety, dosage, and measurable benefits.
Broader implications for a widespread disease
The implications extend beyond the lab. The World Health Organization reported that 57 million people were living with dementia in 2021, with nearly 10 million new cases emerging each year. Alzheimer’s disease accounts for about 60 to 70 percent of these cases worldwide.
In France, the Inserm estimates that around 1 to 1.2 million individuals are affected by the illness, with 225,000 new diagnoses annually. These figures highlight the urgency for researchers to investigate peripheral signals beyond just targeting amyloid and Tau proteins.
Caution is crucial. An artificial increase in cathepsin B has shown adverse effects in healthy mice, indicating that a beneficial signal in a vulnerable context does not necessarily translate to a general stimulant. The latest measured outcome is simply better-preserved spatial memory in the treated animals.




